
Supplementary Information

An extended interaction site in the neuronal AP180 is responsible for recruitment of AP2 in clathrin mediated endocytosis

Samuel Naudi-Fabra et al.


*Corresponding author. Email: milles@fmp-berlin.de

Supplementary Figures:




$\textbf{Supplementary Figure 1: Disorder analysis of AP180 and divide and conquer approach.} \ \ \textbf{Top:}$


Disorder prediction (IUPred¹) of AP180 along its sequence. The gray box represents the folded ANTH (AP180 N-terminal homology) domain. Stars above the disorder prediction represent putative interaction sites with the clathrin heavy chain terminal domain and with the AP2 appendage domains as indicated in the figure. Illustrated below are the constructs used in this study. The numbers on the left and on the right represent the N-terminal and C-terminal limits of the different constructs (called 'segments'), respectively.




Supplementary Figure 2: Assignment of AP180₂₈₁₋₅₀₀. The ¹H-¹⁵N HSQC of AP180₂₈₁₋₅₀₀ showing the peak assignment. Note that all numbers are shifted by +1 with respect to the protein sequence for cloning reasons. 83% of the non-proline residues have been assigned.




Supplementary Figure 3: Assignment of AP180₃₉₉₋₅₉₈. The ¹H-¹⁵N HSQC of AP180₃₉₉₋₅₉₈ showing the peak assignment. Note that all numbers are shifted by +1 with respect to the protein sequence for cloning reasons. 81% of the non-proline residues have been assigned.




Supplementary Figure 4: Assignment of AP180₄₇₁₋₇₀₀. The ¹H-¹⁵N HSQC of AP180₄₇₁₋₇₀₀ showing the peak assignment. Note that all numbers are shifted by +1 with respect to the protein sequence for cloning reasons. 75% of the non-proline residues have been assigned.




Supplementary Figure 5: Assignment of AP180₅₄₀₋₇₄₀. The ¹H-¹⁵N HSQC of AP180₅₄₀₋₇₄₀ showing the peak assignment. Note that all numbers are shifted by +1 with respect to the protein sequence for cloning reasons. 70% of the non-proline residues have been assigned.




Supplementary Figure 6: Assignment of AP180₇₂₀₋₈₉₈. The ¹H-¹⁵N HSQC of AP180₇₂₀₋₈₉₈ showing the peak assignment. Note that all numbers are shifted by +1 with respect to the protein sequence for cloning reasons. 71% of the non-proline residues have been assigned.




Supplementary Figure 7: Secondary structure analysis of AP180. Shown are carbon secondary chemical shifts and secondary structure propensities (SSP) calculated from Cα and Cβ chemical shifts². 1: helical conformation, -1: extended conformation, values in between represent intermediate states. Shown are the data of constructs (A) AP180₂₈₁₋₅₀₀ (B) AP180₄₇₁₋₇₀₀ (C) AP180₇₂₀₋₈₉₈. Colored stars indicate putative interaction sites for clathrin (DLL/DLF) and AP2 α - and β 2-appendage domains, respectively (DPF, FxDxF) (legend as in Fig. 1 and Supplementary Fig. 1).




Supplementary Figure 8: Conformational dynamics of AP180 IDR. (A) ¹⁵N R_{1ρ} relaxation of different AP180 segments (blue) compared to the full length IDR (dark blue). Error bars are shown as black lines. (B) Full display of AP180_{IDR} R_{1ρ} (drak blue, error bars in black). (C) Secondary structure propensities (SSP)² calculated and merged from C_{α} and C_{β} chemical shifts of the different AP180 segments. Colored stars indicate putative interaction sites for clathrin (DLL/DLF) and AP2 α - and β2-appendage domains, respectively (DPF, FxDxF) (legend as in Fig. 1 and Supplementary Fig. 1).




Supplementary Figure 9: Relaxation of AP180 in the absence and presence of CHC_{TD}. $R_{1\rho}$ relaxation rates are shown at an AP180 concentration of 100 μ M and at increasing concentrations of CHC_{TD} (color legend shown in (A)). (A) Interaction of different AP180 segments with CHC_{TD}. (B) Interaction of AP180_{IDR} with CHC_{TD}. Hydrophobic residues LFWY are shown as gray points along the sequence in (B). Field strengths (1 H Larmor frequencies) at which the relaxation rates were recorded are shown in the respective plots. Colored stars indicate putative interaction sites for clathrin (DLL/DLF) and AP2 α - and β 2-appendage domains, respectively (DPF, FxDxF) (legend as in Fig. 1 and Supplementary Fig. 1).



Supplementary Figure 10: CPMG relaxation dispersion of AP180₂₈₁₋₅₀₀ with different concentrations of CHC_{TD}. (A) ΔR_2^{eff} as derived from CPMG relaxation dispersion experiments of 100 μ M ¹⁵N AP180₂₈₁₋₅₀₀ with 40% and 150% CHC_{TD} compared to the concentration of AP180₂₈₁₋₅₀₀. Plotted is the difference between R_2^{eff} at CPMG frequencies of 31.35 Hz and 1000 Hz. (B) CPMG curves of AP180₂₈₁₋₅₀₀ with 40% CHC_{TD} for residues 351Leu, 353Leu and 383Gly, the residues showing the highest ΔR_2^{eff} in this experiment. Data were recorded at a ¹H Larmor frequency of 600 MHz. Errors were propagated from the errors of the CPMG experiment.




Supplementary Figure 11: Relaxation of AP180 in the absence and presence of AP2 α . (A) $R_{1\rho}$ relaxation rates of AP180 segments are shown at an AP180 concentration of 50 μ M and at increasing concentrations of AP2 α (color legend shown in (A)). (B) Interaction of the full AP180 $_{IDR}$ with AP2 α . The concentration of AP180 $_{IDR}$ in the absence and presence of 45% AP2 α was 100 μ M and 91 μ M, respectively. Hydrophobic residues LFWY are shown as gray points along the sequence in (B). Field strengths (1 H Larmor frequencies) at which the relaxation rates were recorded are shown in the respective plots. Colored stars indicate putative interaction sites for clathrin (DLL/DLF) and AP2 α - and β 2-appendage domains, respectively (DPF, FxDxF) (legend as in Fig. 1 and Supplementary Fig. 1).




Supplementary Figure 12: Relaxation of AP180 in the absence and presence of AP2\u03b32. (A)

¹⁵N R_{1ρ} relaxation rates are shown at an AP180 concentration of 100 μM and at increasing concentrations of AP2β2 (color legend shown in (A)). **(B)** Interaction of the full AP180_{IDR} with AP2β2. Hydrophobic residues LFWY are shown as gray points along the sequence in (B). Field strengths (1 H Larmor frequencies) at which the relaxation rates were recorded are shown in the respective plots. Colored stars indicate putative interaction sites for clathrin (DLL/DLF) and AP2 α-and β2-appendage domains, respectively (DPF, FxDxF) (legend as in Fig. 1 and Supplementary Fig. 1). Note that NMR resonances around the EIM disappear already at very low concentrations of AP2β2. At high admixtures (> 15%) it was thus not possible to determine R_{1ρ} rates throughout the whole interaction site, leading to apparently comparable rates around the EIM in construct AP180₂₈₁₋₅₀₀ or AP180₃₉₉₋₅₉₈ and the SLiMs in construct AP180₅₄₁₋₇₄₀. Domination of the EIM over SLiMs is obvious in the rates of the full AP180_{IDR} (B).




Supplementary Figure 13: Interaction of AP180₃₉₉₋₅₉₈ with higher concentrations of AP2β2.


Top: Chemical shift perturbations of AP180₃₉₉₋₅₉₈ at increasing concentrations of AP2 β 2. Bottom: Intensity ratios (I/I₀) extracted from 1 H- 15 N HSQC spectra on AP180₃₉₉₋₅₉₈ alone and in the presence of increasing concentrations of AP2 β 2. AP180₃₉₉₋₅₉₈ has been concentrated to 100 μ M in all samples. Color legend for the different AP2 β 2 concentrations are on the right. Colored stars indicate putative interaction sites for clathrin (DLL/DLF) and AP2 α - and β 2-appendage domains, respectively (DPF, FxDxF) (legend as in Fig. 1 and Supplementary Fig. 1).




Supplementary Figure 14: ITC of AP180₃₉₉₋₅₉₈ **with AP2β2 mutants.** Differential heating powers (DP) per injection are shown on top, enthalpy versus molar ratio of the interaction partners are shown in the bottom row. The data are fitted with a 1:1 binding model resulting in the affinities indicated in the respective graphs (K_D values and binding enthalpies ΔH are shown in the respective graphs). The structure of AP2β2 with the different mutations indicated in pink is shown on the right.




Supplementary Figure 15: Assignment of AP2\beta2₇₁₄₋₉₅₀. The ¹H-¹⁵N TROSY of deuterated AP2 β 2₇₁₄₋₉₅₀ showing the peak assignment. Overlapped regions are shown as a zoom below the spectrum and correspond to the boxed regions within the full spectrum of AP2 β 2₇₁₄₋₉₅₀. 62% of the non-proline residues have been assigned.



Supplementary Figure 16: Secondary structure analysis of AP2 β 2₇₁₄₋₉₅₀. (A) Secondary chemical shifts of AP2 β 2₇₁₄₋₉₅₀ and secondary structure propensities (SSP) calculated from C α and C β chemical shifts². 1: helical conformation, -1: extended conformation, values in between represent intermediate states. (B) SSPs plotted into the structure of AP β 2 (PDB 1E42) with a gradient from -1 (red) to +1 (blue). Gray residues are unassigned or prolines.



Supplementary Figure 17: Competition of AP180₃₉₉₋₅₉₈ from AP2β2 binding by AP180₄₇₀₋₅₀₀. (A) 1 H- 15 N HSQC spectrum of 15 N AP180₃₉₉₋₅₉₈ at 100 μM with 10% APβ2 and additionally AP180₄₇₀₋₅₀₀ (color legend is indicated in the figure). (B) Intensity ratio (I/I₀) of AP180₃₉₉₋₅₉₈ peaks in the presence versus the absence of 10% AP2β2 + increasing amounts of AP180₄₇₀₋₅₀₀ (color legend in (C)). (C) 15 N R_{1ρ} relaxation rates of AP180₃₉₉₋₅₉₈ in the presence of 10% AP2β2 with increasing amounts of AP180₄₇₀₋₅₀₀ and AP180₃₉₉₋₅₉₈ alone (color legend is displayed in the figure), measured at a 1 H Larmor frequency of 900 MHz



Supplementary Figure 18: CPMG relaxation dispersion of AP180₃₉₉₋₅₉₈ (100 μ M) with 10% AP2 β 2. Data from all 22 sites showing relaxation dispersion at a 1 H frequency of 600 MHz and 850 MHz were fit using the program Chemex in a global fit, assuming a two-site exchange process

(unbound – bound). The data fitted to k_{ex} = 662±35 s⁻¹ and a population of the bound state p_B = 8.9±0.97 %. Chemical shift difference obtained from the fit were in the range of 0.3 and 1 ppm.

Supplementary Tables:

Supplementary Table 1: List of clathrin binding regions. The regions are centered around the hydrophobic residue within the cluster of increased R_{1p} rates. 10 residues left and right of that central residues were selected. The sequences were then sorted according to apparent affinities; sequences with the highest R_{1p} rates in AP180_{IDR} upon interaction with CHC_{TD} appear first.

371TGGATAWGDLLGEDSLAALSS³⁹¹
660VSSSSASADLLAGFGGSFMAP⁶⁸⁰
584PSIDLFGTDAFSSPPRGASPV⁶⁰⁴
604VPESSLTADLLSVDAFAAPSP⁶²⁴
749GSDLDSSLASLVGNLGISGTT⁷⁶⁹
710SSSFDPSGDLLMPTMAPSGQP⁷³⁰
687PAQNNLLQPNFEAAFGTTPST⁷⁰⁷
554TAAAPPALDIFGDLFDSAPEV⁵⁷⁴
632KAESSGVIDLFGDAFGSSASE⁶⁵²
425VTAATTEVDLFGDAFAASPGE⁴⁴⁵
345SSDLLDLQPDFSGAAAGAAAP³⁶⁵
ALDACSGNDPFAPSEGSAEAA⁴⁸⁵
481SAEAAPELDLFAMKPPETSAP⁵⁰¹

Supplementary Table 2: Residue wise affinities in AP180_{IDR} with CHC_{TD}. 15 N R_{1 ρ} relaxation rates of AP180_{IDR} in the presence of various concentrations of CHC_{TD} (0%, 20%. 60%, 150%) at an AP180 concentration of 100 μ M were plotted against the respective CHC concentration and fitted with a 1:1 binding model (see materials and methods for details, errors represent fitting errors). The highest R_{1 ρ} rates per cluster were used for this analysis, respectively. Note that this apparently highest R_{1 ρ} rate does not necessarily occur at a hydrophobic residue, depending on the exact binding mode of the residue and potentially influenced by spectral overlap within the large AP180_{IDR}. Nonetheless, the determined affinities should represent binding affinities towards individual linear motifs.

Residue number	Residue type	Surrounding amino acids	Affinity ± error (μΜ)
384	D	GE D SL	177 ± 8
670	L	DL L AG	294 ± 67
596	S	FS S PP	1507 ± 1165
615	S	LL S VD	719 ± 335
720	L	DL L MP	732 ± 320
566	D	FG D LF	549 ± 131
436	F	DL F GD	700 ± 58
699	Α	FE A AF	1166 ± 957
639	I	GVIDL	846 ± 307
678	М	SF M AP	576 ± 10±7
378	G	AW G DL	650 ± 83
574	V	PE V AA	817 ± 133
891	D	LA D LN	1248 ± 864
352	L	LD L QP	1011 ± 214
492	F	DLFAM	1170 ± 215
477	А	PFAPS	1374 ± 308

Supplementary Table 3: Residue wise affinities in AP180 with AP2 α . ¹⁵N R_{1p} relaxation rates from AP180₄₇₁₋₇₀₀ in the presence of various concentrations of AP2 α (0%, 10%, 45%, 320%) at an AP180 concentration of 50 μ M were plotted against the respective CHC concentration and fitted with a 1:1 binding model (see materials and methods for details, errors represent fitting errors). The highest R_{1p} rates per cluster were used for this analysis, respectively. Note that this apparently highest R_{1p} rate does not necessarily occur at a hydrophobic residue, depending on the exact binding mode of the residue and potentially influenced by spectral overlap. Nonetheless, the determined affinities should represent binding affinities towards individual linear motifs.

Residue number	Residue type	Surrounding amino acids	Affinity ± error (μΜ)
490	D	ELDLF	278 ± 83
498	E	PP E TS	463 ± 154
561	L	PA L DI	380 ± 47
571	Α	DSAPE	320 ± 60
582	V	PD V AP	414 ± 27
585	S	AP S ID	459 ± 253
596	S	FS S PP	391 ± 79
599	R	PP R GA	234 ± 132
602	S	GA S PV	441 ± 156
615	S	LL S VD	144 ± 28
635	S	AE S SG	196 ± 61
639	I	GVIDL	257 ± 125
648	S	TT S AA	316 ± 58
664	S	SS S AS	416 ± 198
668	D	SA D LL	288 ± 110
669	L	AD L LA	273 ± 74

Supplementary Table 4: Peptides detected by mass spectrometry from AP180 $_{430-500}$ cross-linking experiment. The peptides are sorted with respect to type (crosslink, monolink, looplink or regular peptide). The detected peptides are indicated; numbers in brackets denote the position of the cross-linked lysine within the detected peptide. Their molecular mass is given in daltons (Da) and peptide modifications are indicated. The number in brackets refers to the residue number within the peptide that is modified; counts start from the first peptide and go on to the second; three residues are added in addition if the modification occurs in the second peptide. The detected peptides are then associated to the protein they originate from; in brackets is the position of the cross-linked lysine with respect to the full protein sequence used in the cross-linking experiment. The amino acid sequences of both AP180 $_{430-500}$, as well as AP $_{2714-951}$ are indicated below the table.

Crosslink	Peptide	Peptid	e_Mass	Modifications	Proteins
	1 AAPELDLFAMKPPE(11)-AAPELDLFAMKPPE(11)		3210.598759	Oxidation[M](10)	AP180_430-500(69)-AP180_430-500(69)
	2 AAPELDLFAMKPPE(11)-LDLFAMKPPET(7)		2943.476864	Oxidation[M](10)	AP180_430-500(69)-AP180_430-500(69)
	3 AAPELDLFAMKPPET(11)-LDLFAMKPPE(7)		2943.476864	Oxidation[M](24)	AP180_430-500(69)-AP180_430-500(69)
	4 GSAEAAPELDLFAMKPPE(15)-LQFQIKE(6)		2931.469471	Oxidation[M](14)	AP180_430-500(69)-AP2B2(159)
	5 LDLFAMKPPE(7)-LDLFAMKPPE(7)		2458.264709	null	AP180_430-500(69)-AP180_430-500(69)
	6 LFAMKPPE(5)-LFAMKPPE(5)		2034.032544	Oxidation[M](4);Oxidation[M](15)	AP180_430-500(69)-AP180_430-500(69)
	7 SILKNAAALE(4)-LFAMKPPE(5)		2115.140507	Oxidation[M](17)	AP2B2(240)-AP180_430-500(69)
Monolink	Peptide	Dentid	e_Mass	Modifications	Proteins
MOHOIIIK	1 AAPELDLFAMKPPET(11)	i cpiid	_	Oxidation[M](10)	AP180 430-500(69)
	2 LDLFAMKPPE(7)			Oxidation[M](6)	AP180 430-500(69)
	3 LFAMKPPE(5)			Oxidation[M](4)	AP180 430-500(69)
	4 LFAMKPPET(5)		1189.61727	1 1()	AP180 430-500(69)
	5 LSTGIGMAPGGYVAPKAVWLPAVKAKGLE(16)			Oxidation[M](7)	AP2B2(15)
	6 RQVFLATWKD(9)		1419.763012	1 1()	AP2B2(146)
Looplink	Peptide	Peptid	e_Mass	Modifications	Proteins
	1 LFELSTGIGMAPGGYVAPKAVWLPAVKAKGLEISGTFTHRQGHIYME(19)(27)		5198.684345	Oxidation[M](10);Oxidation[M](46)	AP2B2(15)(23)
	2 LFELSTGIGMAPGGYVAPKAVWLPAVKAKGLEISGTFTHRQGHIYME(27)(29)		5198.684345	Oxidation[M](10);Oxidation[M](46)	AP2B2(23)(25)
Regular					
peptide	Peptide	Peptid	e_Mass	Modifications	Proteins
	1 AAPELDLFAMKPPE		1528.771523	null	AP180_430-500
	2 ACSGNDPFAPSE		1194.473128	null	AP180_430-500
	3 ACSGNDPFAPSEGSAE		1538.606312	null	AP180_430-500

4 AFAASPGEAPAASE	1275.585116 null	AP180_430-500
5 AFAASPGEAPAASEGATAPATPAPVAAALD	2650.29938 null	AP180_430-500
6 APAASEGATAPATPAPVAAALDACSGNDPFAPSE	3095.426095 null	AP180_430-500
7 CHLNADTVSSKLQNNNVYTIAKRNVE	2931.473989 null	AP2B2
8 DGKMERQVFLATWKDIPNE	2277.133124 null	AP2B2
9 FAIQFNKNSFGVIPSTPLAIHTPLMPNQSID	3397.761152 null	AP2B2
10 GATAPATPAPVAAALD	1393.732105 null	AP180_430-500
11 GATAPATPAPVAAALDACSGNDPFAPSE	2569.187392 null	AP180_430-500
12 GATAPATPAPVAAALDACSGNDPFAPSEGSAE	2913.320576 null	AP180_430-500
13 GKMERQVFLATWKDIPNE	2162.106185 null	AP2B2
14 GKMERQVFLATWKDIPNENE	2405.191695 null	AP2B2
15 GQDMLYQSLKLTNGIWILAE	2309.184488 Oxidation[M](4)	AP2B2
16 GSAEAAPELDLFAMKPPE	1872.904707 null	AP180_430-500
17 HHHHHH	841.371277 null	AP2B2
18 ISGTFTHRQGHIYME	1792.843448 Oxidation[M](14)	AP2B2
19 LDLFAMKPPE	1176.59687 Oxidation[M](6)	AP180_430-500
20 LFAMKPPE	948.485873 Oxidation[M](4)	AP180_430-500
21 LFAMKPPET	1033.538633 null	AP180_430-500
22 LFELSTGIGMAPGGYVAPKAVWLPAVKAKGLE	3270.795749 null	AP2B2
23 LFGDAFAASPGE	1181.54728 null	AP180_430-500
24 LFGDAFAASPGEAPAASE	1707.785982 null	AP180_430-500
25 LGGGIGGSPAVGQSFIPSSVPATFAPSPTPAVVSSGLND	3595.827701 null	AP2B2
26 LGGGIGGSPAVGQSFIPSSVPATFAPSPTPAVVSSGLNDLFE	3985.022755 null	AP2B2
27 LGPPVNVPQVSSMQMGAVD	1941.940769 Oxidation[M](15)	AP2B2
28 LGPPVNVPQVSSMQMGAVDLLGGGLD	2551.28935 null	AP2B2
29 LLGDLLNLD	985.556391 null	AP2B2
30 LLGGGLDSLLGSD	1216.641901 null	AP2B2
31 LQFQIKE	905.509052 null	AP2B2
32 LRIQPGNPNYTLSLKCRAPE	2270.207287 null	AP2B2
33 LSTGIGMAPGGYVAPKAVWLPAVKAKGLE	2881.600695 null	AP2B2
34 LSTGIGMAPGGYVAPKAVWLPAVKAKGLEISGTFTHRQGHIYME	4639.431388 null	AP2B2
35 MEQPQVIPSQGDLLGD	1726.831547 null	AP2B2
36 MLYQSLKLTNGIWILAE	1993.082603 null	AP2B2
37 MNFTNKALQHMTD	1550.708939 null	AP2B2
38 PFAPSEGSAE	991.436675 null	AP180_430-500
39 PFAPSEGSAEAAPELD	1587.717239 null	AP180_430-500
40 PLNNLQVAVKNNID	1551.848856 null	AP2B2

41 QPQVIPSQGD	1068.531965 null	AP2B2
42 QPQVIPSQGDLLGD	1466.74848 null	AP2B2
43 RQVFLATWKD	1263.684375 null	AP2B2
44 RQVFLATWKDIPNE	1716.906702 null	AP2B2
45 RQVFLATWKDIPNENE	1959.992212 null	AP2B2
46 SILKNAAALE	1029.593836 null	AP2B2
47 SILKNAAALEHHHHHH	1851.947271 null	AP2B2
48 SLLGSDLGGGIGGSPAVGQSFIPSSVPATFAPSPTPAVVSSGLND	4168.108265 null	AP2B2
49 SLLGSDLGGGIGGSPAVGQSFIPSSVPATFAPSPTPAVVSSGLNDLFE	4557.303319 null	AP2B2
50 TVSSKLQNNNVYTIAKRNVE	2278.214874 null	AP2B2
51 VDLFGDAFAASPGEAPAASE	1921.881329 null	AP180_430-500
52 VSLPLNTLGPVMKMEPLNNLQVAVKNNID	3161.705949 null	AP2B2
53 VSQYIYQVYD	1277.604791 null	AP2B2
54 VSQYIYQVYDSILKNAAALE	2288.180785 null	AP2B2

Amino acid sequence of AP180₄₃₀₋₅₀₀:

GHMTTEVDLFGDAFAASPGEAPAASEGATAPATPAPVAAALDACSGNDPFAPSEGSAEAAPELDLFAMKPPETSLEHHHHHH

Amino acid sequence of AP β 2₇₁₄₋₉₅₁:

GHMIGMAPGGYVAPKAVWLPAVKAKGLEISGTFTHRQGHIYMEMNFTNKALQHMTDFAIQFNKNSFGVIPSTPLAIHTPLMPNQSIDVSLPLNTLGPVMKMEPLNNLQVA VKNNIDVFYFSCLIPLNVLFVEDGKMERQVFLATWKDIPNENELQFQIKECHLNADTVSSKLQNNNVYTIAKRNVEGQDMLYQSLKLTNGIWILAELRIQPGNPNYTLSL KCRAPEVSQYIYQVYDSILKNAAALEHHHHHH

Supplementary References:

- 1. Erdős, G. & Dosztányi, Z. Analyzing Protein Disorder with IUPred2A. *Current Protocols in Bioinformatics* **70**, e99 (2020).
- 2. Marsh, J. A., Singh, V. K., Jia, Z. & Forman-Kay, J. D. Sensitivity of secondary structure propensities to sequence differences between α- and γ-synuclein: Implications for fibrillation. *Protein Sci* **15**, 2795–2804 (2006).